ADVM-043 / Adverum Biotech - LARVOL DELTA

"@AnneFreund3 @Tichelbaecker @jochen_dutzmann @s_heinemann001 @JakobLedwoch @C_Meyer_MD @ViclouiseJ @DavidDuncker @dmatusiewicz @SeddingUni @DrCathaHamm @ChristophMaack @kaschenke @Phiso_de @danielsteven_ep @klinki_hh @mrubini @DjawidHashemi @HolgerNef @doc_cardio @Herzstiftung" (@TRassafMD)

Long-Term Follow-up Study of ADVM-043 (clinicaltrials.gov) - P=N/A | N=6 | Completed | Sponsor: Adverum Biotechnologies, Inc. | Enrolling by invitation ➔ Completed

Trial completion • Alpha-1 Antitrypsin Deficiency • Gene Therapies • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases

Preliminary safety data from ADVANCE clinical study (ADVM-043-01) in alpha 1 antitrypsin (A1AT) deficiency (ESGCT 2018) - No abstract available.

Clinical • Biosimilar

Adverum -29.7% as it ends therapy for A1AT deficiency (SeekingAlpha) - "Adverum...has slid 29.7% after hours after a program update says it's going to end development of its gene therapy for A1AT deficiency."

Discontinued • Stock price • Alpha-1 Antitrypsin Deficiency • Genetic Disorders

ADVANCE: Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency (clinicaltrials.gov) - P1/2; N=6; Completed; Sponsor: Adverum Biotechnologies, Inc.; Active, not recruiting ➔ Completed; N=20 ➔ 6

Clinical • Enrollment change • Trial completion • AAT

ADVANCE: Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency (clinicaltrials.gov) - P1/2; N=20; Active, not recruiting; Sponsor: Adverum Biotechnologies, Inc.; Trial primary completion date: Dec 2018 ➔ Aug 2019

Clinical • Trial primary completion date

Long-Term Follow-up Study of ADVM-043 (clinicaltrials.gov) - P; N=6; Enrolling by invitation; Sponsor: Adverum Biotechnologies, Inc.

New trial